Our probiotics have been developed using a multi-disciplinary approach based on state-of-the-art screening methodology.
Delivery of probiotics, ensuring consumers receive adequate doses of robust live bacteria, is essential to realising the full potential of probiotics. The development of a range of applications and consumer-friendly product formats is one of our core strengths.
Bifidobacterium lactis HN019 (DR10™ ) and Lactobacullus rhamnosus HN001 (DR20™) have been successfully incorporated into powders, yoghurts, drinking yoghurts, cheeses, fruit juices, snacks and beverages around the world.
We put more than 2000 potential candidate bacterial strains through a range of screening criteria in order to select the most suitable strains: Lactobacullus rhamnosus HN001 and Bifidobacterium lactis HN019.
Bifidobacterium lactis HN019 and Lactobacullus rhamnosus HN001 have been studied extensively in vitro, and in vivo to establish beneficial effects[1,2] and safety. Compelling evidence to demonstrate their immune protective properties has been obtained and published in peer reviewed journals. Human clinical trials, including rigorous double-blind placebo-controlled protocols, have been employed to establish benefits in different population groups, especially with regards to effects on immune modulation.
Dietary intervention studies[3,4] in humans have also demonstrated that both Bifidobacterium lactis HN019 and Lactobacullus rhamnosus HN001 not only survive passage through the human gut but also increase the levels of other beneficial bacteria in the gastrointestinal tract. Beneficial effects associated with desirable intestinal microbial populations are well documented.
Tangible clinical benefits around supporting a healthy immune system have been demonstrated for Bifidobacterium lactis HN019 (consumed with galacto-oligosaccharides) in a large, year-long clinical trial involving 634 one to three year old children around supporting a healthy immune system.
Lactobacullus rhamnosus HN001 has emerged as a leading probiotic strain in the treatment or prevention of paediatric allergies, especially eczema (also known as atopic dermatitis). The anti-allergy efficacy of Lactobacullus rhamnosus HN001 is based mainly on a double-blind, randomised, placebo-controlled trial that studied the role of Bifidobacterium lactis HN019 and Lactobacullus rhamnosus HN001 on infant allergy, conducted in New Zealand.
1. Gopal et al Development and commercialisation of Fonterra probiotic strains Australian Journal of Dairy Technology (2005) 60 174-183.
2. Sander M.E Summary of probiotic activities of Bifidobacterium lactis HN019. Journal of Clinical Gasterloenterology (2006) 40:776-783.
3. Gopal et al Effect of consumption of Bifidobacterium lactis HN019 and galacto-oligosaccharides on microflora of gastrointestinal tract in human subjects Nutrition Research ( 2003)23;1313-1328.
4. Tannock et al Analysis of fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Applied and Environmental Microbiology (2000) 66:2578-2588.
5. Xu J and G. Horothy Symbionts Proceeding of National Academy of Science USA (2003) 18:10452-10459.
6. Sazawal et al Efficacy of milk fortified with a probiotics Bifidobacterium lactis (DR10TM) and a prebiotic galacto-oligosaccharide in prevention of morbidity and on nutritional status. Asia Pacific Journal of Clinical Nutrition (2004) 13:28.
7. Sistek et al Is the effect of probiotics on atopic dermatitis confined to food sensitised children? Clinical and Experimental Allergy 36:629-633.
8. Dekker, J. W. et al. Safety aspects of probiotic bacterial strains Lactobacillus rhamnosus HN001 and Bifidobacterium animalis subsp. lactis HN019 in human infants aged 0-2 years. International Dairy Journal 19, 149-154 (2009).
9. Wickens, K. et al. A differential effect of 2 probiotics in the prevention of eczema and atopy: A double-blind, randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology 122, 788-794 (2008).
10. Prescott, S. L. et al. Supplementation with Lactobacillus rhamnosus or Bifidobacterium lactis probiotics in pregnancy increases cord blood interferon-gamma and breast milk transforming growth factor-beta and immunoglobin A detection. Clinical & Experimental Allergy 38, 1606-1614 (2008).